Core Viewpoint - A federal lawsuit has been filed against Elanco Animal Health Inc. and certain executives for allegedly making false and misleading statements regarding the safety and market prospects of their product Zenrelia between November 7, 2023, and June 26, 2024 [1][2]. Group 1: Lawsuit Details - The class period for the lawsuit is defined as November 7, 2023, to June 26, 2024, with a lead plaintiff deadline set for December 6, 2024 [2]. - The complaint claims that Elanco downplayed safety risks associated with Zenrelia, an oral Janus kinase inhibitor, while overstating its potential for a quick U.S. market launch [2]. Group 2: Product Controversy - The controversy began on June 26, 2024, when Elanco announced that Zenrelia's label would include a boxed warning due to safety issues identified during trials with unvaccinated dogs, which is expected to significantly impede product adoption and limit treatment days [3]. - Following this announcement, Elanco's stock fell by over 20% [4]. Group 3: Company Response - During the Q2 earnings call on August 4, 2024, CEO Jeffrey N. Simmons acknowledged that the new label language would "slow the initial product adoption curve" and projected a 25% reduction in treatment days due to limitations related to vaccine usage as outlined in the boxed warning [4].

Core Viewpoint - A lawsuit has been filed against Elanco Animal Health Incorporated and certain senior executives for potential violations of federal securities laws, particularly concerning the FDA approval of key drug treatments [1][2]. Group 1: Lawsuit Details - The lawsuit is pending in the U.S. District Court of Maryland, captioned Barpar v. Elanco Animal Health Incorporated, et al., No. 24-cv-02912 [2]. - Investors have until December 6, 2024, to request to be appointed to lead the case [2]. Group 2: Product Development and FDA Review - Elanco is developing two significant treatments: Zenrelia for dermatitis in dogs and Credelio Quattro, an oral parasiticide for fleas, ticks, and internal parasites [3]. - The company previously stated that the FDA had all necessary data for review and expected approval by the end of June 2024 [4]. Group 3: Stock Price Impact - Following the announcement that the FDA would not approve the drugs as expected, Elanco's stock price fell over 21%, from $17.97 per share on June 26, 2024, to $14.27 per share on June 27, 2024 [5]. - The lawsuit investigates whether Elanco and its executives made materially false or misleading statements regarding the FDA's approval process [5]. Group 4: Legal Representation - Bleichmar Fonti & Auld LLP is representing plaintiffs in this case, operating on a contingency fee basis, meaning no upfront costs for shareholders [6]. - The firm has a strong track record, having recovered significant amounts from other companies in past litigations [7].

NEW YORK, Oct. 31, 2024 /PRNewswire/ -- The Gross Law Firm issues the following notice to shareholders of Elanco Animal Health Incorporated (NYSE: ELAN). Shareholders who purchased shares of ELAN during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointment. Appointment as lead plaintiff is not required to partake in any recovery. CONTACT US HERE: https://securitiesclasslaw.com/securities/elanco-animal-health-incorporated-loss-submission-form/? id=110017&fro ...

NEW YORK, Oct. 30, 2024 (GLOBE NEWSWIRE) -- Levi & Korsinsky, LLP notifies investors in Elanco Animal Health Incorporated ("Elanco" or the "Company") (NYSE: ELAN) of a class action securities lawsuit. CLASS DEFINITION: The lawsuit seeks to recover losses on behalf of Elanco investors who were adversely affected by alleged securities fraud between November 7, 2023 and June 26, 2024. Follow the link below to get more information and be contacted by a member of our team: https://zlk.com/pslra-1/elanco-animal-h ...

NEW YORK, Oct. 29, 2024 (GLOBE NEWSWIRE) -- The Gross Law Firm issues the following notice to shareholders of Elanco Animal Health Incorporated (NYSE: ELAN). Shareholders who purchased shares of ELAN during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointment. Appointment as lead plaintiff is not required to partake in any recovery. CONTACT US HERE: https://securitiesclasslaw.com/securities/elanco-animal-health-incorporated-loss-submission-form/? id=109662 ...

NEW YORK, Oct. 29, 2024 (GLOBE NEWSWIRE) -- Leading securities law firm Bleichmar Fonti & Auld LLP announces that a lawsuit has been filed against Elanco Animal Health Incorporated (NYSE:ELAN) and certain of the Company’s senior executives for potential violations of the federal securities laws. If you invested in Elanco, you are encouraged to obtain additional information by visiting https://www.bfalaw.com/cases-investigations/elanco-animal-health-incorporated. Investors have until December 6, 2024 to ask ...

NEW YORK, Oct. 29, 2024 /PRNewswire/ -- Levi & Korsinsky, LLP notifies investors in Elanco Animal Health Incorporated ("Elanco" or the "Company") (NYSE: ELAN) of a class action securities lawsuit.CLASS DEFINITION: The lawsuit seeks to recover losses on behalf of Elanco investors who were adversely affected by alleged securities fraud between November 7, 2023 and June 26, 2024. Follow the link below to get more information and be contacted by a member of our team:https://zlk.com/pslra-1/elanco-animal-health- ...

SAN FRANCISCO, Oct. 28, 2024 (GLOBE NEWSWIRE) -- A federal lawsuit has been filed in the U.S. District Court of Maryland against Elanco Animal Health Inc. and specific executives, accusing them of making false and misleading statements between November 7, 2023, and June 26, 2024. Hagens Berman urges Elanco Animal Health Incorporated (NYSE: ELAN) investors who suffered substantial losses to submit your losses now. Class Period: Nov. 7, 2023 – June 26, 2024Lead Plaintiff Deadline: Dec. 6, 2024 Visit: www.hbss ...

Core Viewpoint - The Gross Law Firm has issued a notice to shareholders of Elanco Animal Health Incorporated regarding a class action lawsuit alleging misleading statements and omissions related to product safety and approval timelines [1][2]. Group 1: Allegations - The complaint claims that Elanco misrepresented the safety of Zenrelia, an oral inhibitor for canine dermatology, suggesting it was safer than it actually is [1]. - It is alleged that Elanco is unlikely to meet its previously stated timeline for the U.S. approval and commercial launch of Zenrelia and Credelio Quattro, a parasiticide for dogs [1]. - The company's business and financial prospects were reportedly overstated due to these misleading statements, leading to a misrepresentation of the company's public statements [1]. Group 2: Class Action Details - The class period for the lawsuit is defined as November 7, 2023, to June 26, 2024, and shareholders are encouraged to register for participation [1][2]. - The deadline for shareholders to seek lead plaintiff status is December 6, 2024, with no cost or obligation to participate in the case [2]. Group 3: Law Firm Background - The Gross Law Firm is recognized nationally for class action lawsuits, focusing on protecting investors from deceit and fraud [3]. - The firm aims to ensure companies adhere to responsible business practices and seeks recovery for investors affected by misleading statements [3].

Core Viewpoint - Rosen Law Firm is reminding investors who purchased Elanco Animal Health securities during the specified Class Period of the upcoming lead plaintiff deadline for a class action lawsuit [1] Group 1: Class Action Details - The class action lawsuit against Elanco alleges that the company made false and misleading statements regarding the safety and approval timelines of its products, Zenrelia and Credelio Quattro, which led to overstated business prospects [3] - Investors who purchased Elanco securities between November 7, 2023, and June 26, 2024, may be entitled to compensation without any out-of-pocket fees through a contingency fee arrangement [1][3] - The deadline to move the Court to serve as lead plaintiff is December 6, 2024, and a lead plaintiff acts on behalf of other class members in directing the litigation [1] Group 2: Rosen Law Firm's Credentials - Rosen Law Firm has a strong track record in securities class actions, having achieved the largest settlement against a Chinese company and being ranked No. 1 for securities class action settlements in 2017 [2] - The firm has recovered hundreds of millions of dollars for investors, securing over $438 million in 2019 alone [2] - Founding partner Laurence Rosen was recognized as a Titan of Plaintiffs' Bar by Law360 in 2020, highlighting the firm's expertise in this area [2]